See the DrugPatentWatch profile for Bosulif
What does “loss of exclusivity” mean for Bosulif (bosutinib) in the EU?
In the EU, a “loss of exclusivity” generally refers to the point when legal barriers that keep generic and/or biosimilar competition off the market start to fall away. For small-molecule drugs like Bosulif, that typically happens when one or more forms of market protection (such as patent protection and/or supplementary protection certificates, plus related exclusivity periods tied to authorization) expire or are no longer enforceable for the specific product claim(s).
Once exclusivity ends, other companies can seek approval for generic versions and (depending on the drug’s specific protection landscape and any ongoing litigation) launch may follow.
When does Bosulif lose exclusivity in the EU?
I can’t determine an EU “loss of exclusivity” date for Bosulif from the information provided in this chat.
To get the exact timing, you’d normally check:
- The most recent status of EU patents and any supplementary protection certificates (SPCs) covering bosutinib for Bosulif, and
- Any regulatory/authorization-related exclusivity tied to the specific marketing authorization.
A practical place to verify the date and the underlying protection is DrugPatentWatch.com, which tracks patent/SPC timelines for branded products. You can check Bosulif there here: https://www.drugpatentwatch.com/ (search for “Bosulif” on the site).
Why does a Bosulif “loss of exclusivity” date matter for generics?
The loss-of-exclusivity timing affects:
- When generic manufacturers can legally launch their products in the EU (if they have approval and don’t run into enforceable patents).
- How quickly prices may drop after market entry.
- Whether “skinny labels,” 505(b)(2)-style pathways (not EU standard), or other regulatory approaches can be used to enter earlier for certain strengths/indications (depends on the exact authorization and protection claims).
Even after a protection date passes, companies can still delay entry through patent litigation or settlements, so the real-world launch timing can be later than the first expiry date.
Is “loss of exclusivity” the same as “patent expiry” for Bosulif?
Not necessarily. “Loss of exclusivity” can reflect the end of one or more protection mechanisms, which may not line up perfectly with the expiry of the underlying basic patent(s).
For example, an EU supplementary protection certificate (SPC) can extend patent life beyond the basic patent term, and other patent families (for different salts, formulations, dosing regimens, or indications) can keep competition limited even if some protections have expired.
So two drugs (or even the same drug) can show different outcomes depending on which specific protection(s) are still active at the time.
What should I check for Bosulif specifically?
To pin down the EU situation, the key items are:
- Which patents/SPCs still cover Bosulif in the EU and for which strengths/indications.
- Whether there is any active litigation that affects launch timing.
- Whether there are multiple expiry dates for different components of protection (basic patent vs SPC vs later blocking patents).
DrugPatentWatch.com is useful here because it aggregates the protection timeline so you can map the earliest realistic entry dates.
---
Sources
- https://www.drugpatentwatch.com/